La Trobe

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening

journal contribution
posted on 2025-03-03, 05:51 authored by Wei Jin, Yexuan Deng, John La-MarcaJohn La-Marca, Emily LelliottEmily Lelliott, Sarah Diepstraten, Christina Konig, Lin Tai, Valentina Snetkova, Kristel M Dorighi, Luke Hoberecht, Millicent G Hedditch, Lauren Whelan, Geraldine Healey, Dan Fayle, Kieran Lau, Margaret PottsMargaret Potts, Moore Z Chen, Angus PR Johnston, Yang Liao, Wei ShiWei Shi, Andrew KuehAndrew Kueh, Benjamin Haley, Jean-Philippe Fortin, Marco HeroldMarco Herold
Cas12a is a next-generation gene editing tool that enables multiplexed gene targeting. Here, we present a mouse model that constitutively expresses enhanced Acidaminococcus sp. Cas12a (enAsCas12a) linked to an mCherry fluorescent reporter. We demonstrate efficient single and multiplexed gene editing in vitro, using primary and transformed cells from enAsCas12a mice. We further demonstrate successful in vivo gene editing, using normal and cancer-prone enAsCas12a stem cells to reconstitute the haematopoietic system of wild-type mice. We also present compact, genome-wide Cas12a knockout libraries, with four crRNAs per gene encoded across one (Scherzo) or two (Menuetto) vectors, and demonstrate the utility of these libraries across methodologies: in vitro enrichment and drop-out screening in lymphoma cells and immortalised fibroblasts, respectively, and in vivo screens to identify lymphoma-driving events. Finally, we demonstrate CRISPR multiplexing via simultaneous gene knockout (via Cas12a) and activation (via dCas9-SAM) using primary T cells and fibroblasts. Our enAsCas12a mouse and accompanying crRNA libraries enhance genome engineering capabilities and complement current CRISPR technologies.

Funding

The generation of enAsCas12a mice used in this study was supported by Phenomics Australia and the Australian Government through the National Collaborative Research Infrastructure Strategy (NCRIS) programme. This work was supported by: NHMRC EL1 2017353 (EJL), The Australian Lions Childhood Cancer Research Foundation Grant (EJL & MJH), Austin Medical Research Foundation Grant (EJL), Victorian Cancer Agency ECRF 21006 (STD), NHMRC Investigator Grant 2017971 (MJH), NHMRC Project Grants GNT1159658 (MJH), GNT1186575 (MJH), GNT1145728 (MJH), and GNT1143105 (MJH), and a Cancer Council Victoria Venture Grant (MJH).

History

Publication Date

2025-01-30

Journal

Nature Communications

Volume

16

Article Number

974

Pagination

15p. (p. 1-15)

Publisher

Springer Nature

ISSN

2041-1723

Rights Statement

© The Author(s) 2025. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Usage metrics

    Journal Articles

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC